Journal of Clinical Oncology
Articles in this Issue
RAINFOL-04 (ENGOT-OV96/GOG-3134): A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.
TPS5641 Background: Ovarian cancer (OC) is the eighth leading cause of cancer-related death in women globally. In patients...
Immunonutrition intervention in driver gene–negative non–small cell lung cancer patients with sarcopenia: A randomized controlled trial.
8587 Background: Cancer-related sarcopenia impairs treatment tolerance and survival in advanced NSCLC. This Phase II trial...
Foundation models to bridge the data scarcity and explainability gap in pancreatic cancer diagnosis.
e16003 Background: Deep learning (DL) for medical imaging has traditionally emphasized standard classification metrics, su...
A large-scale, multi-target deep learning model for virtual genomic and molecular risk profiling in colorectal cancer.
3526 Background: Molecular profiling of tumor biopsies is central to precision oncology, informing treatment selection, pr...
Second-line therapeutic strategies following resistance to EGFR-TKIs in advanced EGFR-mutant NSCLC: A systematic review and network meta-analysis.
e20728 Background: After progression on EGFR tyrosine kinase inhibitors (EGFR-TKIs), multiple second-line options exist fo...
HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma.
4190 Background: Nearly 90% pancreatic ductal adenocarcinoma (PDAC) tumors were driven by RAS mutations, including KRAS G1...
MDX-124, a first-in-class annexin-A1 targeting antibody, in patients with locally advanced or metastatic solid malignancies: Data supporting RP2D from the dose escalation stage of a first-in-human phase Ib trial.
e15112 Background: Annexin-A1 overexpression correlates with tumor proliferation and poor prognosis in cancer making it a...
Geodemographic trends and disparities in liver cancer and sepsis-related mortality among adults aged ≥ 45 years in the United States, 1999-2024: A CDC WONDER analysis.
e16163 Background: In the United States, Liver Cancer (LC) is emerging as one of six major cancers with increasing inciden...
Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients.
629 Background: GLP1 Receptor Agonists (GLP1) are widely used for type 2 diabetes (DM2) and obesity in adults. However, da...
Premature cancer mortality in the United States, 1999–2023: Analysis of CDC WONDER data.
11042 Background: Premature cancer deaths (defined as mortality in adults aged 20-69 years) represent significant years of...
Neoadjuvant disitamab vedotin plus carboplatin in HER2-expressing advanced ovarian cancer: A prospective, single-arm, phase II trial.
5556 Background: Standard neoadjuvant paclitaxel-carboplatin for advanced ovarian cancer causes significant neurotoxicity...
A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.
TPS5136 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable dise...
Impact of early intracranial hemorrhage on survival and critical care utilization in acute promyelocytic leukemia: A population-based propensity-matched study.
e18539 Background: Intracranial hemorrhage (ICH) remains a leading cause of early death in acute promyelocytic leukemia (A...
Pre-onset increases in neutrophil-to-lymphocyte ratio as an identifier of mild and severe immune checkpoint inhibitor–related pneumonitis in lung cancer.
e24188 Background: Immune checkpoint inhibitor (ICI)–related pneumonitis is an uncommon but potentially life-threatening t...
Associations between indoor and outdoor air pollution worry and awareness and acceptability of multi-cancer early detection testing: Evidence from a nationally representative US survey.
e22521 Background: Public concern regarding the carcinogenic effects of air pollution has intensified, shaping perceptions...
Efficacy of sonrotoclax vs pirtobrutinib in post–Bruton tyrosine kinase inhibitor (BTKi) relapsed/refractory (R/R) mantle cell lymphoma (MCL): An indirect comparison.
e19050 Background: Sonrotoclax (BGB-11417-201) and pirtobrutinib (BRUIN MCL trial; NCT03740529) have demonstrated efficacy...
Palliative chemotherapy for pancreatic cancer in an integrated healthcare system.
e16371 Background: Palliative systemic therapy for pancreatic ductal adenocarcinoma (PDAC) aims to extend survival and all...
Comprehensive genomic profiling of patients with cancer of unknown primary (CUP).
e15188 Background: Carcinoma of unknown primary (CUP) remains a clinical entity with limited standardized treatment option...
Outcomes of atypical <i>EGFR</i> mutations in early-stage <i>EGFR</i> -mutated non-small cell lung cancer (NSCLC).
8034 Background: Adjuvant osimertinib (osi) improves survival outcomes in patients (pts) with early-stage...
First-in-class PD-1/IL-2 <sup>α-bias</sup> bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non–small cell lung cancer (NSCLC): Updated results from a phase I study.
2618 Background: IBI363 is a first-in-class PD-1/IL-2 α-bias bispecific antibody f...
Education and decision-making autonomy as drivers of HPV screening outcomes in Nepal.
e22574 Background: Cervical cancer screening is uncommon in Nepal due to reasons including resource scarcity, lack of canc...
The impact of reduction in intraoperative frozen sections on positive margin findings in the final pathology report.
e12621 Background: In October 2023, intraoperative frozen section (IOFS) was restricted to breast cancer patients after ne...
A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.
9501 Background: Advances in the neoadjuvant (neo) setting of locoregionally advanced melanoma have recently transformed p...
A nationwide population-based study on the incidence and prognosis of patients with HER2+ breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy.
e12508 Background: The addition of pertuzumab to adjuvant chemotherapy and trastuzumab improves overall survival (OS) of p...
Comparable clinical efficacy of pyrotinib in trastuzumab-naive and trastuzumab-exposed HER2-positive advanced breast cancer patients: A prospective, multicenter, real-world study.
e13025 Background: Pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor that has shown significant efficacy in H...